Brief: Cerus Announces Five-Year FDA Contract For Development Of Next Generation Pathogen Reduction Technology To Treat Whole Blood
13/10/2020 13:40
Oct 13 (Reuters) - Cerus Corp CERS.O :
* CERUS CORPORATION ANNOUNCES FIVE-YEAR FDA CONTRACT FOR THE
DEVELOPMENT OF NEXT GENERATION PATHOGEN REDUCTION TECHNOLOGY TO
TREAT WHOLE BLOOD
* CERUS CORP - CONTRACT VALUE TOTALS $11.1 MILLION
Source text for Eikon: ID:nBw2XWgn8a
Further company coverage: CERS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerus
See all newsCerus Corp reports results for the quarter ended June 30 - Earnings Summary
Cerus Q2 adjusted EBITDA misses estimates, raises 2026 outlook
Brief: Cerus Q2 Gross Profit USD 29.5 Million
Cerus Corp expected to post a loss of 1 cent a share - Earnings Preview
Brief: Cerus Corporation Closes New Debt Facility Of Up To $110 Million